Potential of miR-181a-5p and miR-630 as clinical biomarkers in NSCLC.

BMC Cancer · 2023 · PMC10496384 · PMID 37697308

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Moreover, as specified by miRDB: the microRNA database, BCL2, LMO3, PTEN, SNAI2, WIF1 are also molecular targets of miR-630 and may be significant in NSCLC progression [ 19 ].

also in 7,717 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.